Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …

In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …